
-
Xencor Inc NasdaqGM:XNCR Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Location: 465 North Halstead Street, Pasadena, CA, 91107, United States | Website: https://www.xencor.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
303.1M
Cash
469.6M
Avg Qtr Burn
-40.39M
Short % of Float
13.70%
Insider Ownership
1.22%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obexelimab (CD19) Details Lupus nephritis | Phase 3 Update | |
XmAb942 Details Inflammatory bowel disease | Phase 2b Initiation | |
Plamotamab (CD20xCD3) Details Autoimmune disease, Rheumatoid arthritis | Phase 1/2 Initiation | |
XmAb541 (CLDN6 x CD3) Details Ovarian cancer, Solid tumor/s | Phase 1 Data readout | |
Plamotamab (CD20xCD3) Details Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, B-cell malignancies | Phase 1 Data readout | |
XmAb808 + pembrolizumab Details Solid tumor/s, Prostate cancer | Phase 1 Data readout | |
XmAb819 (ENPP3 x CD3) Details Renal cell carcinoma | Phase 1 Data readout | |
XmAb662 (IL12-Fc) Details Cancer, Solid tumor/s | Phase 1 Update | |
XmAb657 Details Autoimmune disease | Phase 1 Initiation | |
XmAb564 (IL-2-Fc) Details Autoimmune disease, Psoriasis, Atopic dermatitis | Phase 1a Update | |
Tidutamab (SSTR2xCD3) Details Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors | Failed Discontinued | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Vibecotamab (CD123xCD3) Details Acute myeloid leukemia | Failed Discontinued | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Renal cell carcinoma, Cancer, Prostate cancer | Failed Discontinued |